This article is more than 5 years old. Information may no longer be current.
VIDEO: Peter Voorhees, MD, reviews ‘extremely important’ proteasome inhibition data from ENDEAVOR
Click Here to Manage Email Alerts
Peter Voorhees, MD, director of the myeloma program at the University of North Carolina in Chapel Hill and associate professor at the University of North Carolina Lineberger Comprehensive Cancer Center, discusses proteasome inhibition in multiple myeloma.
In the first of a multi-part video series, he covers data from the ENDEAVOR trial, comparing carfilzomib (Kyprolis, Onyx Pharmaceuticals) plus dexamethasone vs. bortezomib (Velcade, Millennium Pharmaceuticals) plus dexamethasone in patients with relapsed disease and one to three prior lines of therapy.
“This study is extremely important in that it clearly establishes carfilzomib as the most efficacious proteasome inhibitor currently in clinical use,” Voorhees said.
He offers background on both drugs, highlighting the differences in their mechanisms of action and side effect profiles, then goes on to detail the phase 3 randomized study — from population and specific interventions to endpoints sought and patient outcomes.
Voorhees also emphasizes varying adverse events and safety profiles between the two agents, citing peripheral neuropathy and cardiopulmonary toxicities.
“For anyone in whom you’re considering bortezomib and dexamethasone in the relapsed space, you should seriously consider carfilzomib and dexamethasone as well,” he said.